Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma

[1]  A. Rosenwald,et al.  Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma , 2008, Oncogene.

[2]  B. Torbett,et al.  HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation , 2008, British journal of haematology.

[3]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[4]  E. Giné,et al.  Leukemic involvement is a common feature in mantle cell lymphoma , 2007, Cancer.

[5]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Staudt,et al.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Hiddemann,et al.  Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma , 2006, Genes, chromosomes & cancer.

[8]  A. Rosenwald,et al.  Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[10]  Rolph Pfundt,et al.  Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. , 2005, Blood.

[11]  J. Zavadil,et al.  Analysis of transcripts from 17p13.3 in medulloblastoma suggests ROX/MNT as a potential tumour suppressor gene. , 2004, European journal of cancer.

[12]  C. Zahnow,et al.  Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. , 2004, Cancer cell.

[13]  G. Ott,et al.  Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. , 2004, Blood.

[14]  F. Berthold,et al.  Analysis of HIC‐1 methylation and transcription in human ependymomas , 2004, International journal of cancer.

[15]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[16]  Y. Yatabe,et al.  Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer , 2003, Oncogene.

[17]  J. Herman,et al.  Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors , 2003, Nature Genetics.

[18]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[19]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[20]  P. Lorigan,et al.  Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization , 2002, British journal of haematology.

[21]  R.,et al.  Overexpression as a Marker of Poor Prognosis in Mantle Cell Lymphomas With t ( l 1 ; 14 ) ( q 13 ; q 32 ) , 2002 .

[22]  D. Catovsky,et al.  p53 and mdm2 in mantle cell lymphoma in leukemic phase. , 2002, Haematologica.

[23]  J. Delabie,et al.  Loss of chromosome 11q21–23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma , 2001, British Journal of Cancer.

[24]  H. S. Kim,et al.  Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Hayashi,et al.  p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. , 1999, Cancer research.

[26]  S. Clark,et al.  Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. , 1999, Cancer research.

[27]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[28]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Seminars in hematology.

[29]  G. Ott,et al.  Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. , 1998, The American journal of surgical pathology.

[30]  K. Franssila,et al.  Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma , 1998, Genes, chromosomes & cancer.

[31]  K. Tanaka,et al.  Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality , 1998, Leukemia.

[32]  A. López-Guillermo,et al.  Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. , 1998, Cancer.

[33]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[34]  S. Baylin,et al.  HIC1 hypermethylation is a late event in hematopoietic neoplasms. , 1997, Cancer research.

[35]  R. Gascoyne,et al.  Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.

[36]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[37]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[39]  A. Godwin,et al.  Identification of two candidate tumor suppressor genes on chromosome 17p13.3. , 1996, Cancer research.

[40]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[41]  D C Louie,et al.  p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). , 1995, Blood.

[42]  S. Baylin,et al.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 , 1995, Nature Genetics.

[43]  P. Lichter,et al.  Detection of chromosomal aberrations by means of molecular cytogenetics: painting of chromosomes and chromosomal subregions and comparative genomic hybridization. , 1995, Methods in enzymology.

[44]  J.M. Adams,et al.  Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. , 1994, The EMBO journal.

[45]  A. López-Guillermo,et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. , 1994, Blood.

[46]  D. Wynford‐Thomas.  P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[47]  M. Raffeld,et al.  bcl-1, t(11;14), and mantle cell-derived lymphomas. , 1991, Blood.

[48]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[49]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[50]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[51]  É.,et al.  Genotypic Characterization of Centrocytic Lymphoma : Frequent Rearrangement of the Chromosome 11 bcl-1 Locus , 2022 .